Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 4/20 | 0.51 |
| ▸ | CTSL | P07711 | 3/20 | 0.50 |
| ▸ | CTSS | P25774 | 3/20 | 0.50 |
| ▸ | CTSK | P43235 | 3/20 | 0.50 |
| ▸ | CTSH | P09668 | 1/20 | 0.50 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.50 |
| ▸ | MC4R | P32245 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29630628 | 0.99 | APLNR (0.49) | APLNRCTSLCTSSCTSKCTSH | |
| SCHEMBL29607754 | 0.92 | APLNR (0.56) | APLNRCTSLCTSSCTSKCTSH | |
| SCHEMBL29606819 | 0.91 | APLNR (0.57) | APLNRCTSLCTSSCTSKCTSH | |
| SCHEMBL29607035 | 0.91 | APLNR (0.55) | APLNRCTSLCTSSCTSKCTSH | |
| SCHEMBL29607506 | 0.91 | APLNR (0.56) | APLNRCTSLCTSSCTSKCTSH | |
| SCHEMBL31683844 | 0.89 | APLNR (0.46) | APLNRCTSLCTSSCTSKCTSH | |
| SCHEMBL31290257 | 0.89 | MC4R (0.55) | APLNRCTSLCTSSCTSKCTSH | |
| SCHEMBL30442638 | 0.89 | F2 (0.51) | APLNRCTSLCTSSCTSKCTSH | |
| SCHEMBL29608384 | 0.89 | APLNR (0.56) | APLNRC5AR1MC4R | |
| SCHEMBL30339898 | 0.88 | CTSL (0.53) | APLNRCTSLCTSSCTSKCTSH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited (GB) | 2026-05-05 | — | — | US | disclosed |
| US-20220112547-A1 | BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS | Biocrucible Limited (GB) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | POLM, POLR1A, POLR1E | APLNR 934/4885CTSL 1435/4885CTSS 2894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.